SLAMF7 and Miyoshi myopathy: A linked single-chain variable fragment (scFv) NKCE, known as CS1xNKG2D, which targets CS1 (also called SLAMF7, a tumor antigen expressed on MM), has been demonstrated to induce dose-dependent cytotoxicity against CS1+ MM cells in vitro, stimulate IFN-γ production, and enhance the survival of NSG mice implanted with human MM cells (54).